Regeneron Pharmaceuticals (MEX:REGN) Cyclically Adjusted Revenue per Share: MXN0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:REGN Regeneron Pharmaceuticals Inc MEX:REGN
87 GF Score
Price MXN12,692.00
GF Value MXN15,070.11
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Cyclically Adjusted Revenue per Share?

Regeneron Pharmaceuticals MEX:REGN +17.13% 87 Cyclically Adjusted Revenue per Share is MXN0.00 as of Jun. 2026. GuruFocus rates MEX:REGN with a GF Score™ of 87/100 and a GF Value™ of MXN15,070.11 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was MXN706.306. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Regeneron Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 12.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 20.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 24.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Regeneron Pharmaceuticals was 41.60% per year. The lowest was 1.40% per year. And the median was 21.55% per year.

As of today (2026-07-31), Regeneron Pharmaceuticals's current stock price is MXN12692.00. Regeneron Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN0.00. Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Regeneron Pharmaceuticals was 30.79. The lowest was 5.23. And the median was 12.16.


Regeneron Pharmaceuticals  (MEX:REGN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Regeneron Pharmaceuticals was 30.79. The lowest was 5.23. And the median was 12.16.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Regeneron Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Regeneron Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,157.25 1,306.26 1,329.99 1,852.78 1,785.58

Regeneron Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,815.76 1,830.36 1,785.58 1,790.82 0.00

MEX:REGN vs RVMD, ALNY, ONC: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


MEX:REGN
87GF Score
Regeneron Pharmaceuticals Inc MEX:REGN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regeneron Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=706.306/333.9520*333.9520
=706.306

Current CPI (Jun. 2026) = 333.9520.

Regeneron Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 202.563 241.428 280.193
201612 218.988 241.432 302.907
201703 215.760 243.801 295.542
201706 228.814 244.955 311.947
201709 232.715 246.819 314.869
201712 268.798 246.524 364.125
201803 238.993 249.554 319.819
201806 275.951 251.989 365.708
201809 270.337 252.439 357.629
201812 62.018 251.233 82.438
201903 230.525 254.202 302.847
201906 264.466 256.143 344.803
201909 301.437 256.759 392.062
201912 307.486 256.974 399.595
202003 372.438 258.115 481.864
202006 382.157 257.797 495.049
202009 444.923 260.280 570.858
202012 429.940 260.474 551.223
202103 467.775 264.877 589.762
202106 923.168 271.696 1,134.701
202109 623.323 274.310 758.849
202112 895.760 278.802 1,072.951
202203 521.999 287.504 606.331
202206 504.221 296.311 568.273
202209 523.596 296.808 589.121
202212 583.411 296.797 656.446
202303 499.972 301.836 553.170
202306 475.348 305.109 520.284
202309 516.530 307.789 560.437
202312 512.706 306.746 558.179
202403 453.477 312.332 484.867
202406 563.113 314.175 598.560
202409 630.479 315.301 667.774
202412 695.655 315.605 736.095
202503 557.210 319.799 581.870
202506 637.280 322.561 659.785
202509 642.441 324.800 660.543
202512 649.392 324.054 669.227
202603 603.668 330.213 610.503
202606 706.306 333.952 706.306

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN0.00 mean?
Regeneron Pharmaceuticals (MEX:REGN) has a Cyclically Adjusted Revenue per Share of MXN0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Regeneron Pharmaceuticals' current Cyclically Adjusted Revenue per Share is MXN0.00. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to RVMD and ALNY?
Regeneron Pharmaceuticals' Cyclically Adjusted Revenue per Share of MXN0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Cyclically Adjusted Revenue per Share is MXN0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (MEX:REGN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN15,070.11, compared to a current price of MXN12,692.00 — trading 15.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN0.00. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Regeneron Pharmaceuticals (MEX:REGN), the current Cyclically Adjusted Revenue per Share is MXN0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (MEX:REGN) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of MXN12,692.00 is trading 15.8% below its estimated GF Value™ of MXN15,070.11. GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:REGN:

  • Cyclically Adjusted Revenue per Share: MXN0.00
  • GF Value™: MXN15,070.11 vs. price of MXN12,692.00 (15.8% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the MEX:REGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score

Get the complete analysis for MEX:REGN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN12,692.00
Price
MXN15,070.11
GF Value